Continuing with his commentary on the second quarter, Mr. Dodd stated, "During the first quarter of this year, we made the decision to raise a significant amount of capital to see us through the next 18 months of the implementation of our strategy. As a result, we are in a strong financial position with cash and cash equivalents of approximately $45.5 million as of June 30. However, the pressure being exerted on our stock price since our public offering does not reflect this strong cash position, our recent achievements and overall corporate value. We believe that the dilution attributable to warrants issued in the offering during the first quarter is the reason for the pressure on our stock price and that such dilution could continue for the next several months. Nonetheless, we remain focused on our upcoming drug development and commercial milestones which we believe will enable us to ultimately achieve our goal of becoming a commercially operating specialty biopharmaceutical company."
Commenting on the filing, David A. Dodd, Chairman, President and Chief Executive Officer of the Company stated, ?The Shelf Prospectus is intended to give us the ability to access new capital in the future. Taking into account our current operations and capital requirements, the offering we completed earlier this month is expected to provide sufficient capital to see us through the first quarter of 2017.
Ich denk du bist im Skiurlaub !? Solltest du diesen dann nicht einfach genießen? Wär doch schade drum - die Aeterna läuft uns schon nicht weg, zumindest momentan nicht ;-)
@cent #76: ja - schade um den Avatar - seh ich auch so, war irgendwie spooky, wie der auf seinem Rad so um die Ecke kam. Hat mich immer an die genialen Tim Burton Filme erinnert, angriffslustig, ein wenig gruselig, anders als andere, aber immer und vor allem geistreich...